Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label eczema. Show all posts
Showing posts with label eczema. Show all posts

Monday, February 19, 2024

High levels of niacin linked to heart disease, new research suggests

 

When I was on this drug in a clinical trial it flared up my eczema so bad I quit the trial.

Ask your competent? doctor if this use of niacin for  Alzheimer's prevention is more important that the risk of heart disease. S/he has had two years to figure out what human trials have been done and their results. If they don't know that; you don't have a functioning stroke doctor!

Intake of FDA-Approved Drug Modulates Disease Progression in Alzheimer’s Model

 March 2022

The latest here:


High levels of niacin linked to heart disease, new research suggests

High levels of niacin, an essential B vitamin, may raise the risk of heart disease by triggering inflammation and damaging blood vessels, according to new research.

The report, published Monday in Nature Medicine, revealed a previously unknown risk from excessive amounts of the vitamin, which is found in many foods, including meat, fish, nuts, and fortified cereals and breads.

The recommended daily allowance of niacin for men is 16 milligrams per day and for women who are not pregnant is 14 milligrams per day.

About 1 in 4 Americans has higher than the recommended level of niacin, said the study’s senior author, Dr. Stanley Hazen, chair of cardiovascular and metabolic sciences at the Cleveland Clinic’s Lerner Research Institute and co-section head of preventive cardiology at the Heart, Vascular and Thoracic Institute.

The researchers currently don’t know where to draw the line between healthy and unhealthy amounts of niacin, although that may be determined with future research.

"The average person should avoid niacin supplements now that we have reason to believe that taking too much niacin can potentially lead to an increased risk of developing cardiovascular disease,” Hazen said.

Currently, Americans get plenty of niacin from their diet since flour, grains and cereals have been fortified with niacin since the 1940s after scientists discovered that very low levels of the nutrient could lead to a potentially fatal condition called pellagra, Hazen said.

Prior to the development of cholesterol-lowering statins, niacin supplements were once even prescribed by doctors to improve cholesterol levels.

To search for unknown risk factors for cardiovascular disease, Hazen and his colleagues designed a multipart study that included an analysis of fasting blood samples from 1,162 patients who had come into a cardiology center to be evaluated for heart disease. The researchers were looking for common markers, or signs, in the patients’ blood that might reveal new risk factors.

The research resulted in the discovery of a substance in some of the blood samples that is only made when there is excess niacin.

Meat in grocery store (Burke/Triolo Productions / Getty Images)
Meat in grocery store (Burke/Triolo Productions / Getty Images)

That finding led to two additional “validation” studies, which included data from a total of 3,163 adults who either had heart disease or were suspected of having it. The two investigations, one in the U.S. and one in Europe, showed that the niacin breakdown product, 4PY, predicted participants’ future risk of heart attack, stroke and death.

The final part of the study involved experiments in mice. When the rodents were injected with 4PY, inflammation increased in their blood vessels.

The results are “fascinating” and “important,” said Dr. Robert Rosenson, director of metabolism and lipids for the Mount Sinai Health System in New York City.

The newly detected pathway to heart disease might lead to the discovery of a medication that could reduce blood vessel inflammation and decrease the likelihood of major cardiovascular events, he added.

Rosenson hopes that the food industry will take note and “stop using so much niacin in products like bread. This is a case where too much of a good thing can be a bad thing.”

The new information could influence dietary recommendations for niacin, said Rosenson, who was not involved with the Cleveland Clinic research.

Scientists have known for decades that a person’s cholesterol level could be a major driver of heart disease, said Dr. Amanda Doran, an assistant professor of medicine in the division of cardiovascular medicine at the Vanderbilt University Medical Center.

Even when patients’ cholesterol levels were brought down, some continued to have a high risk of heart attacks and stroke, Doran said, adding that a 2017 trial suggested that the increased risk might be related to blood vessel inflammation.

Doran was surprised to learn that niacin could be involved in driving up the risk of heart disease.

“I don’t think anyone would have predicted that niacin would have been pro-inflammatory,” she said. “This is a powerful study because it combines a variety of techniques: clinical data, genetic data and mouse data.”

Finding the new pathway may allow future researchers to discover ways to reduce blood vessel inflammation, Doran said.

“It’s very exciting and promising,” she said.

This article was originally published on NBCNews.com


Thursday, March 24, 2022

Intake of FDA-Approved Drug Modulates Disease Progression in Alzheimer’s Model

 With your excellent chance of getting dementia, you'll want your doctor to be following this closely. Do not self treat,

Your risks of dementia, has your doctor told you of this?

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018

Where are the  protocols to prevent your dementia?

 

When I was on this drug in a clinical trial it flared up my eczema so bad I quit the trial.

The latest here:

Intake of FDA-Approved Drug Modulates Disease Progression in Alzheimer’s Model


Summary: Niaspan, an FDA-approved drug, limits disease progression in lab models of Alzheimer’s disease.

Source: Indiana University

Indiana University School of Medicine researchers have found that niacin limits Alzheimer’s disease progression when used in models in the lab, a discovery that could potentially pave the way toward therapeutic approaches to the disease.

The study, recently published in Science Translational Medicine, investigates how niacin modulates microglia response to amyloid plaques in an Alzheimer’s disease animal model.

Gary Landreth, Ph.D., Martin Professor of Alzheimer’s Research, and Miguel Moutinho, Ph.D., postdoctoral fellow in Anatomy, Cell Biology and Physiology, led the study.

“This study identifies a potential novel therapeutic target for Alzheimer’s disease, which can be modulated by FDA-approved drugs,” Moutinho said. “The translational potential of this strategy to clinical use is high.”

Niacin, which sustains metabolism throughout the body, is mainly obtained through a typical diet; it also can be taken in supplements and cholesterol-lowering drugs. The brain, however, Moutinho found, uses niacin in a different manner.

In the brain, niacin interacts with a highly-selective receptor, HCAR2, present in immune cells physically associated with amyloid plaques. When niacin—used in this project as the FDA-approved Niaspan drug—activates the receptor, it stimulates beneficial actions from these immune cells, Landreth said.

This shows a finger touching a picture of a brain
Niacin, which sustains metabolism throughout the body, is mainly obtained through a typical diet; it also can be taken in supplements and cholesterol-lowering drugs. Image is in the public domain

“After the Alzheimer’s disease animal models received niacin, they ended up with fewer plaques and they have improved cognition,” Landreth said, “and we directly showed that these actions were due to the HCAR2 receptor.”

Past epidemiology studies of niacin and Alzheimer’s disease showed that people who had higher levels of niacin in their diet had diminished risk of the disease, Landreth said. Niacin is also currently being used in clinical trials in Parkinson’s disease and glioblastoma.

To further their research into niacin and the brain, Landreth and Moutinho are collaborating with Jared Brosch, MD, associate professor of clinical neurology, who is applying for a clinical pilot trial to study the affects of niacin and the human brain.

About this neuropharmacology and Alzheimer’s disease research news

Author: Press Office
Source: Indiana University
Contact: Press Office – Indiana University
Image: The image is in the public domain

Original Research: Open access.
The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer’s disease” by Miguel Moutinho et al. Science Translational Medicine

 
 

Wednesday, June 13, 2018

Severe, active atopic eczema linked to cardiovascular outcomes

Once again proving that the medical world is woefully uniformed about stroke.  The WHO reclassified stroke in 2006, now a neurological disease not cardiovascular disease.

https://www.mdlinx.com/cardiology/top-medical-news/article/2018/06/12/7524336/?
Reuters Health News
Adults with severe and predominantly active atopic eczema face an increased long-term risk of cardiovascular disease (CVD), according to new findings.
"Adult patients with eczema were 10%-20% more likely to experience non-fatal CVD than people without eczema, and . . . risk increased with more severe and active disease," Dr. Sinead M. Langan of the London School of Hygiene and Tropical Medicine, in the UK, told Reuters Health by email.
About 10% of adults have atopic eczema, and prevalence is increasing globally, Dr. Langan and her team note in The BMJ, online May 23. Systemic inflammation due to the skin condition could be associated with other illnesses, they add, including CVD. But studies of the association between atopic eczema and CVD have had conflicting results.
To further investigate the association, and determine whether atopic eczema severity or activity might influence risk, the researchers compared more than 387,000 patients with atopic eczema and 1.5 million matched controls. Follow-up was a median 5.1 years.
Stroke risk was increased by 20% among patients with severe atopic eczema. Those with severe disease were also at 40% to 50% greater risk of myocardial infarction, unstable angina, atrial fibrillation, and death due to CVD, and had a 70% higher risk of heart failure.
Patients whose eczema was active more than half of the time at follow-up also had an increased risk of CVD-related outcomes.
"Clinically, patients with severe atopic eczema often have poor sleep and experience high levels of stress, which may help to explain the association," Dr. Langan said.
More research is needed on the mechanism behind the association, she added, and whether eczema treatments may modify CVD risk.
—Anne Harding

Sunday, June 3, 2018

Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: Population based cohort study

The WHO reclassified stroke in 2006, now a neurological disease not cardiovascular disease.
Can't our researchers keep up with events in their field? 
Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: Population based cohort study
BMJSilverwood RJ, et al. | May 25, 2018
Researchers investigated if adults with atopic eczema are at an increased risk of cardiovascular disease and if the risk varies by atopic eczema severity and condition activity over time. Severe and predominantly active atopic eczema was found to be related to an increased risk of cardiovascular outcomes. Considering targeting cardiovascular disease prevention strategies among these patients was recommended.

Methods

  • In this population based matched cohort study, researchers included adults with a diagnosis of atopic eczema, matched (on age, sex, general practice, and calendar time) to up to five patients without atopic eczema.
  • They used UK electronic health records from the Clinical Practice Research Datalink, Hospital Episode Statistics, and data from the Office for National Statistics, 1998–2015, to assess cardiovascular outcomes (myocardial infarction, unstable angina, heart failure, atrial fibrillation, stroke, and cardiovascular death).

Results

  • A total of 387,439 patients with atopic eczema were matched to 1,528,477 patients without atopic eczema.
  • At cohort entry, the median age was 43 and 66% were female.
  • The median follow-up was 5.1 years.
  • Cox regression stratified by matched set offered evidence of a 10% to 20% increased hazard for the non-fatal primary outcomes for patients with atopic eczema.
  • A strong dose-response association with severity of atopic eczema was found.
  • The findings observed in patients with severe atopic eczema included a 20% increase in the risk of stroke (hazard ratio 1.22, 99% confidence interval 1.01 to 1.48), 40% to 50% increase in the risk of myocardial infarction, unstable angina, atrial fibrillation, and cardiovascular death, and 70% increase in the risk of heart failure (hazard ratio 1.69, 99% confidence interval 1.38 to 2.06).
  • A greater risk of cardiovascular outcomes was observed in patients with the most active atopic eczema (active >50% of follow-up).
  • The point estimates were partially reduced by additional adjustment for cardiovascular risk factors as potential mediators, though associations persisted for severe atopic eczema.
Read the full article on BMJ

Wednesday, November 5, 2014

Eczema patients face increased risk of accidental injury

My eczema exploded upon taking Niacin as part of a clinical research trial. I never did take any drugs to combat it. I pretty much controlled it by applying coconut oil on it for a week.
http://www.feinberg.northwestern.edu/news/2014/10/Silverberg-accident-prone-eczema.html
Intense itching and dry, irritable skin aren’t the only problems adults with eczema face. They are at greater risk of accidental bone fractures and other injuries, a new Northwestern Medicine study has found.
This is the first study to find adult eczema is a risk factor for fractures and other injuries.
The increased odds of accidental injury could be directly related to the side effects of steroids and sedating antihistamines commonly prescribed to treat the skin disorder or the under-treatment of severe cases, study authors suggest.
“Many eczema patients who are prescribed medication for itch are often given sedating antihistamines or steroids, but those medications may come at a price,” said Jonathan I. Silverberg, MD, PHD, MPH, assistant professor in Dermatology, Medical Social Sciences and Preventive Medicine and senior author of the study. “Sedatives cause fatigue, and steroids can lead to bone density problems and osteoporosis.”
The study, published Oct. 29 in the journal JAMA Dermatology, validates what Dr. Silverberg sees regularly at the Northwestern Multidisciplinary Eczema Center.
“Last month three of my patients with eczema cancelled at the last minute because of injuries,” he said. “One fell and almost got hit by a bus, another was hit by a car and then another missed her appointment because she was in a car accident. You can't make this stuff up.”
More than 10 percent of adults have eczema, which also is called atopic dermatitis. A third of those people report a moderate- to-severe form of the skin condition. The itch eczema patients experience can be maddening.

More at link.

Wednesday, July 16, 2014

3 Things to Know About Niacin and Heart Health

I was in the American clinical trial, but because I got the maximum dose I got the maximum side effects of blowing up my eczema into a scratching bleeding red mess. I dropped out of the trial just as they were closing it down.
http://well.blogs.nytimes.com/2014/07/16/3-things-to-know-about-niacin-and-heart-health/

Monday, July 29, 2013

Cardio Notes: Niacin and Stroke Risk

I was in this AIM-HIGH trial and dropped out just as it was shutting down. I believe that the niacin totally flared up a patch of eczema on my leg, causing me to scratch it until it bled.
But see what your doctor thinks.
http://www.medpagetoday.com/Cardiology/Strokes/40725?